Skip to main content
Log in

Validation of an LC-MS/MS method for the determination of zopiclone, N-desmethylzopiclone and 2-amino-5-chloropyridine in whole blood and its application to estimate the original zopiclone concentration in stored specimens

  • Original Article
  • Published:
International Journal of Legal Medicine Aims and scope Submit manuscript

Abstract

2-Amino-5-chloropyridine (ACP) is a degradation product of zopiclone (ZOP) and its two main metabolites N-desmethylzopiclone (NDZOP) and zopiclone N-oxide (ZOPNO). ACP may be formed when specimens are stored. ZOP instability in blood makes interpretation of concentrations difficult especially in cases of prolonged sample storage. This study investigated how ACP could be used to estimate the original concentration of ZOP in authentic samples. For that purpose, an analytical liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the quantitation of ACP, ZOP, and NDZOP in blood was developed and validated. Due to poor extraction recovery, ZOPNO was not included in the analytical method. The method was then applied to investigate ACP formation, ZOP and NDZOP degradation in stored ZOP post-dosed authentic whole blood and two mathematical models were used to calculate the original concentration of ZOP. During storage, ACP was formed in amounts equimolar to the ZOP and NDZOP degradation. Results from samples in which ACP had been formed were used to test two models to estimate the original ZOP concentration. The correlation tests of the models showed strong correlations to the original ZOP concentration (r = 0.960 and r = 0.955) with p < 0.01 and explained more than 90 % of the ZOP concentration. This study showed that the equimolar degradation of ZOP and NDZOP to ACP could be used to estimate the original concentration of ZOP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Mannaert E, Tytgat J, Daenens P (1997) Detection of 2-amino-5-chloropyridine in urine as a parameter of zopiclone (Imovane) intake using HPLC with diode array detection. J Anal Toxicol 21:208–212

    Article  CAS  PubMed  Google Scholar 

  2. Nilsson GH, Kugelberg FC, Ahlner J, Kronstrand R (2014) Quantitative analysis of zopiclone, N-desmethylzopiclone, zopiclone N-oxide and 2-amino-5-chloropyridine in urine using LC-MS-MS. J Anal Toxicol. doi:10.1093/jat/bku042

    PubMed  Google Scholar 

  3. Jantos R, Vermeeren A, Sabljic D, Ramaekers JG, Skopp G (2013) Degradation of zopiclone during storage of spiked and authentic whole blood and matching dried blood spots. Int J Legal Med 127:69–76

    Article  PubMed  Google Scholar 

  4. Galloway JH, Marsh ID, Newton CM, Forrest AR (1999) A method for the rapid detection of the zopiclone degradation product 2-amino-5-chloropyridine. Sci Justice 39:253–256

    Article  CAS  PubMed  Google Scholar 

  5. Fernandez C (1995) Degradation and racemisation of zopiclone enantiomers in plasma and partially aqueous solutions. Chirality 7:267–271

    Article  CAS  Google Scholar 

  6. Nilsson GH, Kugelberg FC, Kronstrand R, Ahlner J (2010) Stability tests of zopiclone in whole blood. Forensic Sci Int 200:130–135

    Article  CAS  PubMed  Google Scholar 

  7. Nilsson GH, Kugelberg FC, Ahlner J, Kronstrand R (2011) Influence of pre-analytical conditions on the interpretation of zopiclone concentrations in whole blood. Forensic Sci Int 207:35–39

    Article  CAS  PubMed  Google Scholar 

  8. Holmgren P, Druid H, Holmgren A, Ahlner J (2004) Stability of drugs in stored postmortem femoral blood and vitreous humor. J Forensic Sci 49:820–825

    Article  CAS  PubMed  Google Scholar 

  9. Mistri HN, Jangid AG, Pudage A, Shrivastav P (2008) HPLC-ESI-MS/MS validated method for simultaneous quantification of zopiclone and its metabolites, N-desmethyl zopiclone and zopiclone-N-oxide in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 864:137–148

    Article  CAS  PubMed  Google Scholar 

  10. Jones AW, Holmgren A, Kugelberg FC (2007) Concentrations of scheduled prescription drugs in blood of impaired drivers: considerations for interpreting the results. Ther Drug Monit 29:248–260

    Article  CAS  PubMed  Google Scholar 

  11. Gustavsen I, Al-Sammurraie M, Morland J, Bramness JG (2009) Impairment related to blood drug concentrations of zopiclone and zolpidem compared to alcohol in apprehended drivers. Accid Anal Prev 41:462–466

    Article  PubMed  Google Scholar 

  12. Vindenes V, Lund HM, Andresen W, Gjerde H, Ikdahl SE et al (2012) Detection of drugs of abuse in simultaneously collected oral fluid, urine and blood from Norwegian drug drivers. Forensic Sci Int 219:165–171

    Article  CAS  PubMed  Google Scholar 

  13. Jones AW, Holmgren A (2012) Concentrations of zolpidem and zopiclone in venous blood samples from impaired drivers compared with femoral blood from forensic autopsies. Forensic Sci Int 222:118–123

    Article  CAS  PubMed  Google Scholar 

  14. Jones AW, Holmgren A, Ahlner J (2012) Toxicological analysis of blood and urine samples from female victims of alleged sexual assault. Clin Toxicol (Phila) 50:555–561

    Article  CAS  Google Scholar 

  15. Gaillot J, Heusse D, Hougton GW, Marc Aurele J, Dreyfus JF (1983) Pharmacokinetics and metabolism of zopiclone. Pharmacology 27(Suppl 2):76–91

    Article  CAS  PubMed  Google Scholar 

  16. Fernandez C, Martin C, Gimenez F, Farinotti R (1995) Clinical pharmacokinetics of zopiclone. Clin Pharmacokinet 29:431–441

    Article  CAS  PubMed  Google Scholar 

  17. Gunja N (2013) The clinical and forensic toxicology of Z-drugs. J Med Toxicol 9:155–162

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. El-Shaheny RN, Alattas A, Nasr JJ, El-Enany N, Belal F (2012) Simultaneous determination of zopiclone and its degradation product and main impurity (2-amino-5-chloropyridine) by micellar liquid chromatography with time-programmed fluorescence detection: preliminary investigation for biological monitoring. J Chromatogr B Analyt Technol Biomed Life Sci 907:49–55

    Article  CAS  PubMed  Google Scholar 

  19. Peters FT, Drummer OH, Musshoff F (2007) Validation of new methods. Forensic Sci Int 165:216–224

    Article  CAS  PubMed  Google Scholar 

  20. Gebauer MG, Alderman CP (2002) Validation of a high-performance liquid chromatographic method for the enantiospecific quantitation of zopiclone in plasma. Biomed Chromatogr 16:241–246

    Article  CAS  PubMed  Google Scholar 

  21. Tonon MA, Jabor VA, Bonato PS (2011) Enantioselective analysis of zopiclone and its metabolites in plasma by liquid chromatography/tandem mass spectrometry. Anal Bioanal Chem 400:3517–3525

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank the National Board of Forensic Medicine and the Centre of Forensic Science Linköping University for providing resources for this study.

Conflict of interest

There were no external sources of funding for this project. None of the authors consider that any conflicts of interest exist.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Gunnel H. Nilsson.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nilsson, G.H., Kugelberg, F.C., Ahlner, J. et al. Validation of an LC-MS/MS method for the determination of zopiclone, N-desmethylzopiclone and 2-amino-5-chloropyridine in whole blood and its application to estimate the original zopiclone concentration in stored specimens. Int J Legal Med 129, 269–277 (2015). https://doi.org/10.1007/s00414-014-1049-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00414-014-1049-2

Keywords

Navigation